Michel Kahaleh, MD

Michel Kahaleh, MD

Dr. Kahaleh is the Clinical Director of Gastroenterology and Chief of Endoscopy at Rutgers Robert Wood Johnson. Trained in Erasme Hospital, University of Brussels, he became the leader of the Pancreatico-Biliary group at the University if Virginia before joining Well Cornell in July 2011 as Chief of Endoscopy until December 2017.

He is world renown endoscopist boarded in Europe and the United States. He is fluent is French, Spanish and Arabic. Dr. Kahaleh's research is focused on interventional endoscopy, and the use of new devices to diagnose and treat biliary and pancreatic diseases. Using the adjunction of both Endoscopic Retrograde Cholangiopancreatography (ERCP) and Endoscopic Ultrasonography (EUS) has permitted his group to successfully treat pancreatic collections and perform newly described procedures that have had a major impact on patient management.

A major focus of his research is on preventing and treating complications of advanced endoscopic procedures. He is actively analyzing the efficacy of metallic stents in both benign and malignant diseases. Another area of investigation for Dr. Kahaleh is understanding and preventing biliary and pancreatic cancer.

The objective of this area of research is to develop new diagnostic techniques for reducing the mortality associated with those cancers, by detecting them earlier and treating them using novel therapies such as laser therapy and radiofrequency ablation.

He is pioneering minimally invasive procedures involving therapeutic EUS , ESD and POEM locally and internationally. He is also teaching those techniques across the globe.


Related Videos

Endoscopic Management of Hilar Cholangiocarcinoma, Clinical Evidence Overview and Case Review Video Presentation, Michel Kahaleh, M.D. Video

Endoscopic Management of Hilar Cholangiocarcinoma, Clinical Evidence Overview and Case Review Video Presentation, Michel Kahaleh, M.D.

Accuracy and cost effectiveness in stricture diagnostics, and a multidisciplinary approach to palliative treatment for non-resectable disease, including stenting, RFA, and mapping with cholangioscopy.